Ipsen S.A. publishes its 2022 Universal registration document

Announcement 22 April 2024 5 mins read

Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases

Regulated Information 17 April 2024 4 mins read

Ipsen publishes its 2023 Universal Registration Document

Regulated Information 08 April 2024 1 mins read

Ipsen – Monthly information relative to the total number of voting rights and shares composing the share capital

Announcement 02 April 2024 7 mins read

Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors

Regulated Information 07 March 2024 1 mins read

Ipsen – Monthly information relative to the total number of voting rights and shares composing the share capital

Corporate 15 February 2024 1 mins read

Ipsen S.A. publishes its 2023 Consolidated Financial Statements

Corporate 13 February 2024 14 mins read

Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA  

Corporate 08 February 2024 8 mins read

Building on solid FY 2023 results, Ipsen anticipates four launches in 2024

Regulated Information 06 February 2024 1 mins read

Ipsen – Monthly information relative to the total number of voting rights and shares composing the share capital

Corporate 22 January 2024 10 mins read

Latest Phase III trial data investigating Cabometyx® in combination with immunotherapy to be presented at ASCO GU 2024